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ABSTRAK 
Indeks Prognosis Antarabangsa {IPI) telah diketengahkan untuk menstratumkan risiko 
pesakit limfoma bukan Hodgkin (NHL) dan mengenalpasti subset pesakit berisiko tinggi 
yang mungkin tidak dapat bertindakbalas terhadap kemoterapi dengan memuaskan. IPI 
telah dibentuk berlandaskan model populasi pesakit berbangsa barat. Kami telah 
menlaksanakan suatu kajian longitudinal melibatkan pesakit NHL aggresif yang 
menerima rawatan di Hospital USM dari I haribulan J anuari 1990 ke 31 haribulan 
Disember 2000. Kajian ini hanya melibatkan pesakit berbangsa Melayu. Ini bertujuan 
untuk menguji kesesuaian penggunaan IPI ke atas etnik tersebut. Ciri-ciri klinikal 
sepertimana yang telah diuji dalam model IPI yang asal, telah diuji ke atas kohort kami. 
Pencapaian pesakit dari segi kadar respons sempurna (complete response rate : CR), 
kadar kemandirian keseluruhan (overall survival rate: OS) dan kadar kemandirian bebas 
penyakit (disease free survival rate: DFS) bagi setiap faktor eli atas telah eli olah. Pada 
masa yang sama data-data yang diperolehi telah digunakan untuk membentuk profit 
penyakit NHL dalam populasi kami. 
Daripada sejumlah 102 pesakit NHL, hanya 88 pesakit mempunyai keputusan 
histopatologi yang boleh dibaca untuk analisis pengkelasan. 7 5 (85o/o) adalah NHL 
aggresif jenis tersebar. 29% dari semua limfoma yang menjalani ujian imunofenotip 
terdiri dari limfoma sel-T. 
Kohort seramai 45 pesakit limfoma Melayu telah dikenalpasti untuk analisis. 51% 
mengalami limfoma ekstranodal primer. Rangkaian Waldeyer's merupakan tapak 
ekstranodal yang paling kerap dicerobohi iaitu 18o/o dari semua pencerobohan, diikuti 
oleh saluran pemakanan, tulang dan sum sum tulang setiap satu 11%. Selepas tamat 
rawatan kemoterapi CHOP, 51% dari pesakit mencapai respons sempurna (CR) dan 33% 
mencapai respons separa (PR). Respons keseluruhan ialah 84o/o. Kadar kemandirian 3-
tahun ialah 45o/o manakala 5-tahun pula ialah 24%. 
Setiap faktor klinikal telah di kaji dari segi hubungkaitnya dengan CR, OS dan DFS. 
Hanya status keupayaan cergas (ECOG 0 & 1) eli dapati mempunyai hubungan 
bersignifikan dengan kadar CR yang lebih baik berbanding degan status keupayaan lemah 
(ECOG 2- 4) p = 0.007. RR = 3.0 (95% CI 1.27 -7.14). Jantina lelaki, umur pesakit di 
bawah 60, tahap perebakan terhad, saiz tumor yang tidak boyot, status keupayaan cergas, 
paras hemoglobin darah yang rendah, dan paras laktat dehydrodegenase (LDH) dan 
albumin dalam darah yang normal di dapati berhubungkait dengan kadar CR yang lebih 
baik tetapi hubungan ini kesemuanya tidak bersignifikan. 
Status keupayaan cergas, kehadiran gejala B dan paras LDH dalam darah yang tinggi 
(>500iu/L) eli dapati berhubungkait secara signifikan dengan kadar kemandirian 
keseluruhan (OS) yang lebih lama (P=O.OOOI, 0.02, 0.037) berbanding dengan 
pengenapnya iaitu status keupayaan lemah, ketiadaan gejala B dan paras LDH darah yang 
normal. Pencapaian lebih awal respons sempurna klinikal iaitu berikutan pusingan ketiga 
kemoterapi juga di dapati berhubungkait dengan kadar kemandirian keseluruhan yang 
lebih lama (P=O.Ol7). Melalui analisis multivariate regresi Co~ hanya status keupayaan 
cergas berhubungkait secara bersignifikan dengan kadar kemandirian keseluruhan. 
(P=O.Ol). Nisbah hazad bagi status keupayaan cergas ialah 0.242 (95% CI: 0.083- 0.71). 
Kami tidak berjaya menunjukkan hubungkait yang bersignifikan secara statistik di antara 
anemia dengan kadar CR, OS dan DFS disebabkan kekurangan kuasa statistik di dalam 
kajian. 
Hanya jantina perempuan di dapati mempunyai hubungkait yang signifikan secara 
statistik dengan kadar kemandirian bebas penyakit (DFS) (P=0.034). Walau 
bagaimanapun kenyataan ini adalah tidak sah disebabkan oleh jumlah pesakit yang kecil 
di mana maklumat jangka kemandirian bagi semua pesakit perempuan terd.iri dari data 
tapis (censured data). 
Secara ringkasnya, jumlah pesakit untuk kajian yang kecil telah mengakibatkan kajian ini 
mempunyai kuasa statistik yang lemah untuk menguji kenyataan-kenyataan hipotesis 
yang diajukan. Hanya status keupayaan sahaja di buktikan dapat meramal risiko 
kemandirian. Kajian ini menunjukkan faktor-faktor lain yang di ketengahkan oleh IPI, 
juga mempunyai corak hubungan dengan kadar kemandirian sepertimana yang 
diperhatikan pada model asal IPI. Walau bagaimanapun, hubungan ini tidak berupaya 
menunjukkan perbezaan yang signifikan desebabkan oleh kajian yang kurang kuasa 
statistik. Justeru itu, kami perkesimpulan bahawa kajian ini tidak dapat menunjukkan 
sebarang tanda yang boleh merencatkan penggunaan IPI dalam populasi kami. 
Sungguhpun demikian, memandangkan kadar kehadiran limfoma ekstra-nodal primer 
yang tinggi, model IPI tiga tahap yang telah di cadangkan untuk populasi pesakit Cina 
mungkin lebih wajar digunakan berbanding dengan model IPI empat tahap yang asal. 
ABSTRACT 
International prognostic index (IPI) was introduced to risk stratify non-Hodgkin 
lymphoma (NHL) patients and to identify high-risk patient who might not respond 
favorably to standard chemotherapy. IPI was modeled from a Caucasian based patient 
population. We undertook a single center, observational longitudinal study involving all 
available patients with aggressive NHL who had received treatment from Hospital USM 
between 1st Jan 1990 and 31st Dec 2000. We confined our study to adult Malay patients 
to test the applicability of IPI in this racial group. Individual presenting clinical features 
was categorized as in the IPI study, and the patients' outcome in terms of complete 
response (CR), overall survival (OS) and disease free survival (DFS) rates for each of the 
above features were determined. At the same time the available data was used to 
characterize NHL disease profile in our patient population. 
From a total of 102 patients with NHL, only 88 patients had readable histopathology, in 
which 75 (85o/o) was diffuse aggressive NHL. T-celllymphomas constitute 29o/o of all 
NHL with immunophenotype studies. 
A final cohort of 45 Malay patients with aggressive NHL was established, 51% were of 
primary extra-nodal lymphoma. W aldeyer' s ring was the commonest extra-nodal site 
involved (18%) followed by gastrointestinal tract, bone and marrow llo/o each. 51% and 
33% achieved complete clinical response (CR) and partial response (PR) correspondingly 
following CHOP chemotherapy. Overall response rate was 84%. 3-years survival rate 
was 45% and 5-years survival rate was 24%. 
Individual clinical characteristics were studied in terms of its association with complete 
response rate (CR), overall survival rates (OS) and disease free survival rates (DFS). 
Only good performance status (ECOG 0 & 1) were found to be significantly associated 
with better CR rates compared to poor perfonnance status (ECOG 2 to 4) p=0.007. 
RR=3.0 (95%CI 1.27 - 7.14). Male sex, age less than 60, limited disease, non bulky 
disease, good performance status, low hemoglobin, normal serum lactate dehydrogenase 
(LDH) and albumin were associated with higher CR rates but statistically not significant. 
Good performance status, presence of B symptoms and elevated serum LDH (>500iu/L) 
were shown to be significantly associated with longer OS (P= 0.0001, 0.02, 0.037) 
compared to poor performance status, absence of B symptoms and normal serum LDH. 
Early achievement of clinical complete response following 3rd cycle of chemotherapy was 
also associated with longer overall survival (P=0.017). With Cox regression analysis, 
only good performance status was significantly associated with overall survival. (P=0.01). 
The hazard ratio for good performance status was 0.242 (95o/oCI: 0.083- 0.71). 
We were not able to show statistically significant association between anemia with CR, 
OS and DFS rates due to poor statistical power. 
Only female gender was shown to have a significant association with bt(tter DFS rates 
(P=0.034) but this outcome was erroneous due to small patient numbers, il_l which 
survival data from the female gender group only consisted of censured data. 
In summmy, due to limited number of availaple patient for this study, we lacked 
statistical power to test our hypothesis. Only performance status was proven to 
prognosticate survival risk. Our study showed similar trends in survival outcome for 
other factors proposed in IPI, mimicking the trends seen in the IPI model. However 
these trends were not marked enough to become statistically significant in a poorly 
powered study. At this juncture, we conclude that there is no evidence to show that IPI is 
not applicable in our patient population. However, in the presence ofhigh proportion of 
primary extra-nodal lymphoma the modified three tiers IPI suggested for Chinese 
population may be a more appropriate option compared to the four tiers IPI. 
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INTRODUCTION 
Non-Hodgkin lymphoma (NHL) consists of a family of heterogenous tumors with 
variable clinical course, shared by a common pathogenesis resulting from 
malignant clonal proliferation of cells in the lymphoid series. The fourth quarter 
of the twentieth century saw considerable evolution in the classification of NHL. 
The Working Formulation (Rosenberg SA et al, 1982) was preferred in the United 
States whereas Kiel's classification (Gerard-Marchant R et al, 1974) was more 
popular in Europe. 
Working Formulation utilizes morphological features alone and was found to have 
predictive value for survival. The clinical outcomes of different categories vary 
considerably and are collectively graded into three groups; low grade, 
intermediate grade and high grade. For an overview see Table 1.1. 
1.1 Aggressive NHL 
In general, the high-grade subtypes have destructive growth pattern with frequent 
involvement of privileged sites (i.e. central nervous system, testes, etc). The 
lymphoma cell's cytology is atypical and anaplastic. From the clinical point of 
view, they are aggressive with shorter survival if without therapy and B symptoms 
are more common. Fortunately, they are more responsive to combination 
chemotherapy with better long-term remission and probable cures. 
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Table 1.1. Table showing Working Formulation for NHL. Adapted from 
(Rosenberg, SA. et aL (1982)) 
Low grade 
A. Malignant lymphoma, small lymphocytic 
a Consistent with CLL 
b. Plasmacytoid 
B. Malignant lymphom~ follicular, predominantly small cleaved cell 
a Diffuse areas 
b. Sclerosis 
C. Malignant lymphoma, follicular, mixed, small cleaved and large cell 
a Diffuse areas 
b. Sclerosis 
Intermediate group 
D. Malignant lymphom~ follicular predominantly large cell 
a. Diffuse areas 
b. Sclerosis 
E. Malignant lymphoma, diffuse small cleaved cell 
a Sclerosis 
F. Malignant lymphoma, diffuse mixed, small and large cell 
a Sclerosis 
b. Epitheloid cell component 
G. Malignant lymphoma, diffuse large cell 
a Cleaved cell 
b. Noncleaved cell 
c. Sclerosis 
High grade 
H. Malignant lymphoma, large cell, immunoblastic 
a Plasmacytoid 
b. Clear cell 
c. Polymorphous 
d. Epitheloid cell component 
I. Malignant lymphoma, lymphoblastic 
a Convoluted cell 
b. Nonconvoluted cell 
J. Malignant lymphoma, small noncleaved cell 
a Burkitt's 
b. Follicular areas 
Miscellanous 
Composite 
Mycosis fungoides 
Histiocytic 
Extramedullar plasmacytoma 
Unclassifiable 
Other 
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Distinctly, the low-grade subtypes are non destructive with an indolent clinical 
course, at times with spontaneous remission. The malignant cells cytology 
appears to resemble normal lymphoid population. 
From the clinical perspective, cases are viewed either as indolent or aggressive 
lymphoma The former include working formulation categories A, B, C, D and E 
and the later includes the remaining categories. Categories J and I are at times 
described as highly aggressive lymphoma Aggressive lymphoma in spite of its 
terrifying expression can achieve cure with combination chemotherapy. However 
the responses are variable and have to be individualized, taking into account of 
numerous prognostic factors besides morphology. On the other hand, cure is a 
concept still foreign in indolent lymphoma. 
One of the main drawbacks in Working Formulation was that different clinical 
entities of NHL are morphologically grouped together, into its respective working 
formulation categories. Their clinical behavior and response to treatment varies. 
Therefore the accumulated information over the years led to redefinition of 
disease entities reflecting both its clinical and pathological characteristics. Hence 
Working Formulation had been superseded by REAL and later WHO 
classification of NHL. 
Kiel's classification (Table 1.2) was a separate system with emphasis on exact 
histogenesis, especially in its utilization of immunophenotyping in differentiating 
B from T cell lymphomas. Unfortunately it was not very useful in predicting 
clinical outcome. (Richards & Stansfeld, 1988) 
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Table 1.2. Oassification of NHL under Kiel's classification and its equivalent counterpart 
under the Working Formulation. 
Low grade neoplasia High grade neoplasia 
Lyrnpho~c,chronic A Centroblastic G lyrnpho~dlleukemia 
L~pho~c,o~er A L~phoblastic, Burkitt's J 
_type 
L~phaplasmacytoid A Lymphoblastic, I 
convoluted cell type 
Centro~c E Lymphoblastic, other (unclassified) 
Centroblastic-centrocytic, Immunoblastic H follicular without sclerosis 
Centroblastic-centrocytic, High grade malignant lymphoma, 
follicular wi~ sclerosis B unclassified Centroblastic-centrocytic, c follicular and diffuse, D 
without sclerosis 
Centroblastic-centrocytic, 
follicular and diffuse, with 
sclerosis 
Centroblastic-centrocytic, F diffuse 
Low _grade malignant l~phoma, unclassified 
Malignant lymphoma, unclassified (unable to specify high grade to low grade) 
Composite lymphoma 
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1.2 NHL in Asia 
Among malignant lymphomas, Hodgkin's lymphomas were reported to be 
relatively common in western population with prevalence between 40.9% (Lee 
and Spratt, 1974) and 43.6% (Lennert, 1978). In Asian series however, Hodgkin's 
lymphomas only constituted 6%, 8.5% and 9.2% of the Japanese (Kaelin et al, 
1983 ), Thailand (Sukpanichnant S et al, 1998) and Hong Kong (Ho et al, 1984) 
studies respectively. Therefore NHLs fonns the bulk of malignant lymphomas 
seen in Asian populations. 
Geographically related variation in clinical and histopathological presentation in 
NHL is a recognized phenomenon. Burkitt's lymphomas, small intestinal 
lymphomas, and T -cell lymphomas are recognized entities which predominate in 
tropical Africa, the Middle East and Japan respectively (Shih and Liang, 1991 ). 
1.2.1 Follicular NHL 
Among NHLs, the incidence of follicular lymphomas is lower in Asian 
populations. Follicular lymphomas consist of 8.8%, 1 Oo/o and 17.1 o/0 of all 
NHL in Chinese (Dong et al, 1980), Japanese (Kadin et al, 1983) and 
Hong Kong (Ho et al, 1984) series. On the contrary, it accounted for 44% 
in a US series (Jones et al, 1973) and 21.9% in a European series (Lennert, 
1978). A recent Malaysian pathological report from University Hospital 
consisting of heterogenous East Malaysian ethnic backgroWld showed that 
5 
follicular lymphoma consisted only 5.8% of all NHL (Chai, 1999). The 
rest were of aggressive and highly aggressive variety. 
1.2.2 Immunophenotype characteristics 
Immunophenotype studies revealed contradicting observation in Japan 
compared to Western countries. B-cell lymphomas predominate in 
Western countries where only 10 to 20% ofNHLs are ofT-cell type. In 
contrast the proportion of T -cell lymphomas ranges from more than 70% 
of all NHLs in Kyusu and Southwest Japan to 40% in Nagoya (Kadin et al, 
1983 ). The larger proportion ofT -cell lymphomas/leukemias in Japan has 
been shown to correlate with the higher seroconversion to HTL V -1 
retroviral infection in their population. K yusu and Southwest Japan are 
known to be endemic for HTL V -1 infection. 
Studies on immunophenotype characterization in other parts of Asia 
showed prevalence of T -cell lymphomas comparable to figures derived 
from areas in Japan non-endemic to HTL V -1 infection. The proportion of 
T-celllymphoma was shown to be 39.4 (Shih et al, 1991) to 50o/o (Suet al, 
1988) in Taiwan, 25% (Ho et al, 1984) to 34% (Ng et al, 1988) in Hong 
Kong and 28o/o (Xu et al, 1984) in China. 
Chai (1999) presented a local distribution consisting of 84o/o B cell and the 
remaining 16% T cell NHL. His studied population consisted of 15.8o/o 
Malay, 12.1% Chinese, 1% Indian and 71 o/o indigenous groups of Sabah 
6 
and Sarawak. The immunophenotype distribution mimics the pattern seen 
in Western NHL populations. 
1.2.3 Primary extra-nodal NHL (PENL) 
The frequency of primary extra-nodal NHLs in Asia varied from 28.5 to 
45%. (Shih et al, 1991 ). In a Hong Kong Chinese series, it went as high as 
60.6% more common than lymph node lymphomas. (Mok et al, 1997) the 
commonest site of involvement was the gastrointestinal tract accounting 
for 63% of all extra-nodal NHL (Ho et al, 1984) whereas in Japan it was 
the W aldeyer' s ring. (Kadin et al, 1983 ). In the whole both the 
gastrointestinal tract and W aldeyer' s ring were the commonest sites and 
are in keeping to features seen in Western studies. There has not been any 
clinical data publication on adult lymphoma characterization for the 
Malaysian population. 
1.3 Treatment for Aggressive NHL 
The introduction of the first multi-agent chemotherapy referred as C-MOPP or 
COPP (cyclophosphamide, adriamycin, prednisolone and procarbazine) was a 
major step in the management of patient with aggressive non-Hodgkin lymphoma. 
(De Vita et al, 1975) Its variant which became a widely used regimen, CHOP 
(cyclophosphamide, adriamycin, vincristine and prednisolone) with or without 
radiotherapy showed complete remission (CR) rate of 98o/o and disease free 
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survival (DFS) rate of 84% in patient with clinical stage I and II disease. (Miller 
and Jones, 1983) 
In advanced stage (clinical staging III and IV) disease however, treatment 
outcome was not promising. Treatment with CHOP led to overall CR rate of 51% 
and DFS rate of only 31% ( Annitage et al, 1984 ). Attempts were then made to 
formulate newer multi-agent chemotherapy, hence the birth of second and third 
generation regimens. Independently, MACOP-B, a second-generation regime was 
shown to improve CR rate in aggressive NHL to 84 o/o and DFS rate to 7 5o/o but 
with increased toxicity. When these regimes were compared head to head with 
CHOP, they did not show significant improvement in either CR or DFS rates. A 
direct comparative study evaluating the outcome of CHOP against newer second 
generation regimes including m-BACOD (low dose methotrexate with leucovorin 
rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and 
dexamethasone), ProMACE-CytaBOM (prendisolone, doxorubicin, 
cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, 
and methotrexate with leucovorin rescue), and MACOP-B (methotrexate with 
leucovorin rescue, doxorubicin, cyclophophomide, vincristine, prednisolone and 
bleomycin) showed no significant difference in DFS at three years between each 
group; CHOP and MACOP-B 41%, ProMACE-CytaBOM and m-BACOD 46%. 
Instead, fatal toxic reactions occurred less in CHOP (1 o/o) compared to other 
regimes ProMACE-CytaBOM (3%), m-BACOB (5%) and MACOP-B (6%) 
(Fischer,l993). With regards to this, CHOP remained the mainstay chemo regime 
despite of its not so favourable outcome. 
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In the above study the CR rate, partial response rates and overall survival rates at 
3 years for the CHOP arm were 44%, 36%, and 41% respectively (Fischer, 1993). 
At an average, CHOP regime led to cure in advanced stage aggressive non-
Hodgkin' s lymphoma in less than 40%. 
1.4 Prognosticating NHL 
There will certainly be a group of patient with cure rates even less than those 
presented above. Several methods have been devised to prognosticate and pick 
these unfortunate patients out. The presence or absence of a multitude of features 
has been shown to influence outcome. In fact in Table 1.1, we have seen that 
morphology alone plays a vital role. Several small studies had been carried out 
looking at individual factors and its influence on disease and treatment outcome. 
Among the identified poor prognostic factors included: 
Tumor bulk (Cabanillas et al, 1978); 
Elevated Lactate Dehydrogenase (>5 OOiu/1) (Ferraris et al, 1979); 
Large tumor mass more than 1 Ocm (Fisher et al, 1981 ); 
B symptoms (Fisher et al, 1981); 
Bone marrow involvement (Fisher et al, 1981 ); 
Age > 45 years old (Koziner et al, 1982 ); 
Central nervous system involvement (Littman & Wang, 1975); 
Performance status (Fisher et al, 1981 ); 
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Mediastinal disease (De Vita et al, 197 5) 
And prior chemotherapy (Fisher et al, 1981 ); 
1.4.1 Anemia 
Anemia had been studied and was shown in univariate studies to be an 
independent adverse prognostic factor for overall survival and progression 
free survival regardless of bone marrow involvement or otherwise. 
However in multivariate analyses anemia was a significant prognostic 
factor in overall survival and progression free survival for the whole study 
population and those with bone marrow involvement but not for those 
without bone marrow involvement. (Moullet, 1998) 
1.4.2 Biological markers 
Over the last decade other factors have also been looked into for their 
prognostic value. Among them include various molecular biomarkers such 
as 
• The over-expression of BCL-2 protein and BCL-2 gene 
rearrangement were shown to reduce overall disease survival in 
patients with diffuse large cell~ (Gascoyne, 1997b). 
• The simultaneous expression of Bax protein (a proapoptotic 
member of BCL-2 protein family) and BCL-2 heterodimer was 
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shown to be poor prognostic indicator in diffuse large NHL 
(Gascoyne, 1997a). 
• The presence of high BCL-6 mRNA in tumors with diffuse large 
cell NHL predicts favourable prognosis. Those with high level 
BCL-6 had median overall survival of 171 months compared to 24 
months in those with low level (Lossos, 200 I). 
• The presence of high serum concentrations of vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF) 
were associated with unfavourable outcome with lower 5-years 
survival rate in different grades of lymphoma (Salven, 2000). 
Today biomarker arrays are being used to predict prognosis in NHL patient. In 
centers where facilities are available it has superseded IPI as the main prognostic 
tool. 
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1.5 International prognostic index (IPI) 
1.5.1 Prior to IPI 
Prior to the introduction of IPI, therapies for aggressive lymphoma in adult 
were guided by the borrowed Ann Arbor classification (Table 1.3 ), which 
was originally developed for Hodgkin's lymphoma (Carbone et al, 1971 ). 
Management strategies for localized stage 1 and II disease differed from 
advanced stage III or IV disease. 
The drawback to Ann Arbor classification was based on the fundamentals 
that patterns of disease spread in Hodgkin's differ from NHL. Hodgkin's 
lymphomas are nodal disease and commonly spread through contiguous 
groups of lymph nodes. A significant number of NHL are extra-nodal 
especially in Eastern populations, hence utilization of the above 
classification tends to lead to erroneous conclusions. These shortcomings 
led to the creation and verification of the International Prognostic index as 
described further below. 
1.5.2 The development of IPI 
The international prognostic index is a model in predicting outcome on 
patients with aggressive NHL on the basis of the patient's pretreatment 
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Table 1.3. Hodgkin's Disease: Ann Arbor Staging Classification 
(Carbone et al, 1971) 
Stage I 
Involvement of a single lymph node region (I) or a single 
extralymphatic organ or site (IE) 
Involvement of two or more lymph node regions on the same 
side of the diaphragm (II) or localized involvement of an 
Stage II 
extralymphatic organ or site and of one or more lymph node 
regions on the same side of the diaphragm (liE). An optional 
recommendation is that the number of nodal regions involved be 
indicated by a subscript (e.g., l13) 
Involvement of lymph node regions on both sides of diaphragm 
(III), which may also be accompanied by involvement of the 
spleen (IllS), localized involvement of an extralymphatic organ 
Stage III 
or site (Hie), or both (IIISE). Involvement confmed to the 
spleen or lymph nodes above the celiac axis is designated III 1, 
while lymph node involvement below the celiac axis with or 
without splenic or lymph node involvement above the celiac axis 
is designated III2. 
Diffuse or disseminated involvement of one or more 
Stage IV extralymphatic organs or tissue with or without associated 
lymph node enlargement. 
A or B subclassification 
E subclassification 
The absence or presence of unexplained weight loss of more than 10% 
of body weight in the 6 months prior to diagnosis~ unexplained fever 
with temperature above 38C, or night sweats is denoted by the suffix 
letter A (absence) and B (presence), respectively. 
Designates localized involvement of a single extralymphatic organ or 
site. Liver and bone marrow involvement is always designated as PS 
IV disease 
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clinical characteristics. It is a composite model taking into account the 
various prognostic factors that were known to date to influence outcome. 
Each individual factor was initially studied on 1385 patients from centers 
in United States, Europe and Canada. It was carried out between 1982 
to 1987. Among the factors that were studied included sex, age, Ann Arbor 
staging, site of lymphomatous involvement, extranodal involvement, 
dimension of largest tumor, performance status, B symptoms, serum LDH, 
serum albumin and serum P2 microglobulin level. The above factors were 
evaluated by its influence on response rate, 5 years relapse-free survival 
rate and 5 years overall survival rate with CHOP as the standard 
chemotherapy. 
The five pretreatment characteristics that remained independently 
significant in influencing overall survival were identified; 
Age <= 60 years versus > 60 years 
Localized disease (stage I and II) versus advanced disease (stage III 
or IV) 
The number of extranodal sites of disease ( <= 1 versus > 1) 
Performance status (0 or 1 versus >=2) 
Serum LDH level(<= 1 times nonnal versus >1 times nonnal) 
See Table 1.4 for details 
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Table 1.4. Factors independently Prognostic of Overall Survival in the 
Training Sample of IPI model. (Adapted from Shipp et al, 1993) 
Factors 
No of patients (n = 1385) 
Age ( <=60 vs >60) 
Serum LDH ( <= 1 x normal vs > 1 x 
normal) 
Performance status (0 or 1 vs. 2 - 4) 
Stage (I or II vs III or IV) 
Extranodal involvement ( <= 1 site vs. > 1 
site) 
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Relative Risk 
1.96 
1.85 
1.80 
1.47 
1.48 
P value 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Hence the resulting model incorporate the following features 
1. reflects the growth and invasive potential of the twnor (tumor 
stage, serum LDH level and number of extra-nodal disease 
sites) 
ii. the patients response to the tumor (performance status) 
111. and the patients ability to tolerate intensive therapy (age and 
performance status) 
For each of the above-mentioned factors, a score of 1 point is given for the 
presence of each poor risk feature. A cumulative score following the 
consideration of all the above 5 factors will decide the patients into four 
risk groups. (0-1: Low; 2: Low intermediate risk; 3: High intermediate; 4 
or 5: High risk) The stratification into either one of these four groups was 
shown to directly correlate with complete response rate, relapse-free 
survival and complete survival rates. (See Table 1.5) The lower the risk, 
the higher the complete response, the relapse-free survival and the overall 
survival rate (Shipp, 1993 ). 
A simplified version of age-adjusted IPI was derived from the study 
applicable for those below 60 years old but it will not be dealt with here 
(Shipp, 1993 ). 
IPI was intially based on aggressive NHL (intermediate and part of high 
grade morphology categories based on working fonnulation) and on 
western populations. Since its introduction, it has been shown to be also 
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Table 1.5 Outcome According to Risk Group Defined by the International Index (Adapted from Shipp et al, 1993) 
International index, No of Risk Distribution of COMPLETE RESPONSE SURVIVAL 
n=2031 Factors Patiens o/o RATE(%) RELAPSE-FREE 2-YRRATE 5-YRRATE 
SURVIVAL (%) (o/o) 
2-yrrate 5-yrrate 
(%) (%) 
Low 0 or 1 35 87 79 70 84 73 
Low Intermediate 2 27 67 66 50 66 51 
High Intennediate 3 22 55 59 49 54 43 
High 4 or5 16 44 58 40 34 26 
---------
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applicable in indolent low-grade lymphoma (Hermans, 1995) as well as 
lymphoma complicating AIDS. (Rossi, 1999) 
1.5.3 IPI in Chinese 
Further study was also carried out to validate IPI in Chinese populations. 
It was shown in a study that in the whole, IPI was applicable except for 
extra-nodular involvement, which was found to be non-significant. (Mok 
et al, 1998) This should not come as a surprise as the prevalence of extra-
nodul NHL is higher in eastern populations. Table 1.6 describes further 
their findings. 
Because of the non-significance of the degree of extra-nodal involvement 
in predicting prognosis in this study, a modified version of IPI was 
suggested. Instead of including all five characteristics, overall survival 
curves for three risk groups were constructed using only the first 
significant four. In this model the presence of one or no risk factors are 
classified as low risk, two risk factors as intermediate risk and three or four 
risk factors as high risk. The five years overall survival rates for the low, 
intennediate and high risk groups were 65.5o/o, 45.0o/o and 16.5o/o 
respectively (P<O.OOI). (Mok et al, 1998). 
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Table 1.6. Table showing 5-years survival rate of different prognostic factors in a study on Chinese subjects. (Mok, 1993) 
Studied factors OverallS years survival rates Significance, P 
1 Lactate Dehydrogenase Nonnal Abnormal 
71.9o/o 42.8o/o <0.001 
Age <=60 >60 
62.5% 41.5% 0.004 
Ann Arbor Staging Stg I & II Stg III & IV 
64.1% 4I.8% <0.001 
Perfonnance Status >=80 <=70 
60.4% 33.2% 0.006 
Extranodal involvement 0 & I sites >I sites 
56.3% 41.9% 0.382 
- ~-
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1.6 What if someone has poor IPI indices 
Several areas are being diligently studied to produce viable therapeutic 
options for those expected to respond poorly to standard CHOP 
chemotherapy. Studies to identify new chemo agents, the prevention of 
drug resistance, the introduction of colony stimulating factors and 
monoclonal antibodies into chemotherapy regimes were some of the 
measures undertook to address this issue (Fisher, 2000). The most 
promising advance was however the introduction of ablative chemotherapy 
with stem cells support into the armamentarium 
1.6.1 Ablative chemotherapy with autologous stem-cell support 
1.6.1.1 In Aggressive NHL 
In principle autologous stem-cell transplant functions as a rescue 
mechanism, incorporated into a regime to allow a higher dose of 
intense chemotherapy that leads to myeloablation. 
The preface to the incorporation of marrow stem cell transplant 
was the result of the Parma trial. Although the study was 
conducted on patients with relapse non-Hodgkin lymphoma, it 
paved the way for further studies on untreated lymphomas. 
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98 patients with high-risk, diffuse B-cell lymphomas were included 
in a study comparing high-dose sequential chemotherapy followed 
by myeloablative therapy and hematopoietic stem-cell support 
versus standard MACOP-B protocol. The results were promising. 
Following a median of 55 months, the fonner study group had 
significantly better complete response (96% versus 70o/o) and 
freedom from disease progression (84% versus 49%) and event-
free survival (76% versus 49%). 
However, overall survival after 7 years of follow up was not 
statistically improved (73% versus 62o/o). In terms of fatal toxic 
reactions both groups had similar outcome, 8% in the fonner and 
6% in the later.(Gianni, 1997) Nevertheless, its toxicity is certainly 
higher when compared to standard CHOP regime. 
Between 1991 tol995, 124 patients with aggressive NHL were 
randomized into either one of the following groups. First was the 
conventional chemotherapy group using V ACOP-B (etoposide, 
doxorubicin, cyclophosphamide, vincristine, prednisolone, and 
bleomycin) followed by DHAP ( cisplatin, cytarabine and 
dexamethasone}, if relapsed or failed to achieve remission. 
Secondly was V ACOP-B followed by high dose myeloablation 
therapy and autologous bone marrow transplant. In this study there 
was no significant difference in terms of CR rates (75o/o versus 
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73%); in overall DFS rates (60% versus 80%) or progression-free 
survival rates ( 48% versus 60% ). The 6-years survival probability 
was 65% in both arms. (Santini, 1998). 
Both the above-randomized studies echoed a disappointing 
outcome following an initial excitement from results of 
nonrandomized trials that showed superiority of high-dose 
chemotherapy plus autologous bone marrow transplant over 
conventional therapy. However when these study samples were 
reanalyzed to include only subjects with high-intennediate and 
high risk international prognostic index groups there was a 
statistically significant improvement in disease-free survival and 
progression free survival (Fisher, 2000). 
1.6.1.2 In High Risk IPI Aggressive NHL 
One study although not randomized worked specifically on the 
high risk international prognostic index patients. In this study 
carried out by the Italian Multiregional non-Hodgkin's Lymphoma 
Study Group (IMRNHLSG), 50 patients with diffuse large-cell 
non-Hodgkin Lymphoma classified as high-risk under the 
international prognostic index underwent sequential high-dose 
chemotherapy with autologous bone marrow transplant. 72% 
achieved complete response and at a median of 32 months follow 
up, disease free survival rate was 69o/o and overall survival was 
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56%. (Vitolo, 1997) Prior to the above study, beforel992 
IMRNHLSG treated patients with advanced diffuse large cell 
lymphoma with similar risk profiles with MACOP-B protocol. As 
a historical control, 42% of these patients achieved complete 
remission and the 3-years survival rate was only 29%. (Vitolo, 
1992) 
The above data appear to suggest that, selectively patients with 
non-Hodgkin lymphoma with high risk profile benefit the most 
from upfront high-dose chemotherapy and autologous bone 
marrow transplant 
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2.0 OBJECTIVE OF STUDY 
By the 1990's, haemopoietic stem cell transplant was made available at limited 
centers in Malaysia. Currently, it has already been applied as a treatment option 
for selected patients with acute leukemia and lymphoma Following the 
establishment of our hematology unit in Hospital USM in Kelantan in 1983, we 
are now in the process of upgrading our services to include haemopoetic stem cell 
transplant services. We cater our services mainly for populations in the east coast 
of Malaysia, the state of Kelantan and Terengganu in particular, who are 
predominantly Malay. 
As we have described above, only selected patients with non- Hodgkin's 
lymphoma (NHL) will benefit from high dose chemotherapy and autologous 
marrow transplant. Those with high-risk IPI scores are the ones who will benefit 
the most. However the IPI index was derived from studies on Caucasian 
populations. When the IPI index was validated in a study on Chinese populations, 
extra-nodal involvement was found to be not a significant prognostic factor. We 
are unsure of the utility of IPI in our patient population who are predominantly 
Malay. From our clinical experience we tend to see much more extra-nodal NHL, 
similar to the Chinese study, but this statement will need validation and we intend 
to study this issue in this exercise. 
We included patients from our center with aggressive NHL with similar 
characteristics as to those described in the IPI project into this study. They 
included those treated with either chemotherapy alone or chemotherapy and 
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